COX10 Antibody

Code CSB-PA257877
Size US$166
Order now
Image
  • The image is immunohistochemistry of paraffin-embedded Human renal cancer tissue using CSB-PA257877(COX10 Antibody) at dilution 1/100. (Original magnification: 200)
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
COX10
Alternative Names
2410004F01Rik antibody; AU042636 antibody; COX10 antibody; COX10_HUMAN antibody; Cytochrome c oxidase assembly protein antibody; Cytochrome c oxidase subunit X antibody; Heme A farnesyltransferase antibody; Heme O synthase antibody; OTTMUSP00000006085 antibody; Protoheme IX farnesyltransferase; mitochondrial antibody; Protoheme IX farnesyltransferase; mitochondrial precursor antibody; RP23-78H18.1 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Fusion protein of Human COX10
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,IHC
Recommended Dilution
Application Recommended Dilution
ELISA 1:500-1:2000
IHC 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Converts protoheme IX and farnesyl diphosphate to heme O.
Gene References into Functions
  1. On the basis of its pivotal role in regulating cell death upon COX dysfunction, CerS6 might potentially represent a novel target for therapeutic intervention in mitochondrial diseases caused by COX dysfunction. PMID: 25766330
  2. ISCU and COX10 are target genes of miR-210 related to mitochondrial metabolism PMID: 20498629
  3. COX 15 mRNA was significantly more abundant in the cerebral tissue of Alzheimer's disease (AD) patients and COX10 and COX15 SNP were significantly less represented in the patient group, suggesting a possible protective role toward the risk for AD PMID: 19826901
  4. The expression of the AOX, well-tolerated by the cells, compensates for both the growth defect and the pronounced oxidant-sensitivity of COX-deficient human cells. PMID: 20049701
  5. Cytochrome c oxidase is decreased significantly in platelets and hippocampus in Alzheimer patients compared to controls. PMID: 11959398
  6. COX10 has a role in mitochondrial heme A biosynthesis PMID: 12928484
  7. This study report a cytochrome c oxidase (COX)-deficient patient, clinically affected with Leigh-like disease, with a homozygous mutation in the COX10 start codon. PMID: 15455402
  8. Geranylgeranyltransferase inhibitor-2147 (GGTI-2147), an inhibitor of this enzyme prenylation, elicited significant inhibition of glucose-stimulated insulin secretion from INS 832/13 islet cells. PMID: 17192483

Show More

Hide All

Involvement in disease
Mitochondrial complex IV deficiency (MT-C4D); Leigh syndrome (LS)
Subcellular Location
Mitochondrion membrane; Multi-pass membrane protein.
Protein Families
UbiA prenyltransferase family
Database Links

HGNC: 2260

OMIM: 220110

KEGG: hsa:1352

STRING: 9606.ENSP00000261643

UniGene: Hs.462278

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*